MindWalk Holdings (HYFT) Cash from Discontinued Operations (2024 - 2026)

MindWalk Holdings (HYFT) posted quarterly Cash from Discontinued Operations of 16580.22 for Q4 2025, down 96.21% year-over-year from 437176.35 in Q4 2024, and down 96.98% quarter-over-quarter from 548750.14 in Q3 2025.

MindWalk Holdings (HYFT) Cash from Discontinued Operations (2024 - 2026) Analysis & Trends

MindWalk Holdings (HYFT) has reported Cash from Discontinued Operations for 2 consecutive years, with 16580.22 the latest figure, recorded in Q4 2025.

  • In Q4 2025, Cash from Discontinued Operations fell 96.21% year-over-year to 16580.22; the TTM figure through Apr 2026 stood at 565330.36 (down 62.18% YoY), while the FY2026 annual figure was 566826.18, down 61.73% from the prior year.
  • Cash from Discontinued Operations eased to 16580.22 in Q4 2025 per HYFT's latest filing, from 548750.14 in the prior quarter.
  • Across five years, Cash from Discontinued Operations topped out at 723008.86 in Q3 2024 and bottomed at 16580.22 in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Discontinued Operations (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn -
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn -
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 7.90 Mn
7 Royalty Pharma 33.72 Bn 35.84 Bn - -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -
10 Roivant Sciences 26.16 Bn 26.85 Bn 1.16 Mn -

Historic Data

Download Data
DateValue
Apr 30, 2026 7.90 Mn
Apr 30, 2026 7.90 Mn
Jan 31, 2026 -2.14 Mn
Jan 31, 2026 -2.14 Mn
Oct 31, 2025 16,580.22
Oct 31, 2025 16,580.22
Jul 31, 2025 548,750.14
Jul 31, 2025 548,750.14
Apr 30, 2025 334,498.86
Apr 30, 2025 334,498.86
Oct 31, 2024 437,176.35
Oct 31, 2024 437,176.35
Jul 31, 2024 723,008.86
Jul 31, 2024 723,008.86